FLI1 gene influences lesion size and skin test may predict therapeutic response in cutaneous leishmaniasis

• Published in: Memórias do Instituto Oswaldo Cruz Vol. 115; p. e190361
• Main Authors: da Hora, Anadilton Santos, de Almeida, Lucas Frederico, do Lago, Tainã Souza, Machado, Paulo Roberto, Castellucci, Léa Cristina
• Format: Journal Article
• Language: English
• Published: Brazil Instituto Oswaldo Cruz, Ministério da Saúde 01-01-2020; Fundação Oswaldo Cruz (FIOCRUZ)
• Subjects: Adolescent; Adult; Antimony - therapeutic use; Antiprotozoal Agents - therapeutic use; Case-Control Studies; Female; FLI1gene; Genetic Predisposition to Disease; Genotype; Humans; leishmaniasis; Leishmaniasis, Cutaneous - drug therapy; Leishmaniasis, Cutaneous - genetics; Leishmaniasis, Cutaneous - pathology; Male; Middle Aged; PARASITOLOGY; Polymorphism, Single Nucleotide; Retrospective Studies; Short Communication; Skin Tests; therapeutic response; TROPICAL MEDICINE; Wound Healing - genetics; Young Adult; leishmaniasis; therapeutic response; FLI1gene
• ISSN: 0074-0276; 1678-8060; 1678-8060
• DOI: 10.1590/0074-02760190361

Genes associated with wound healing have been shown to be risk factors for cutaneous leishmaniasis (CL) which is caused by Leishmania braziliensis. In this study, we examined whether the genes previously associated with CL influenced the clinical outcome. Patients were genotyped and retrospectively classified as responders, who were cured with a single course of pentavalent antimony (Sbv), or as refractories, who did not respond to Sbv. Patients characterised as responders showed a stronger response to the leishmanin skin test (LST) when compared to the refractory subjects (p = 0.0003). Furthermore, we observed an association between the FLI1 CC genotype and an increased size of ulcers (p = 0.0170). We suggest that the leishmanin skin test may be a predictive tool for therapeutic outcome and reinforce FLI1 as a potential influencer of susceptibility and lesion size in CL.